Cohance Lifesciences Ltd — Q4 FY26
Cohance Lifesciences reported FY26 revenue of ₹22.68B, down 13% YoY, with adjusted EBITDA margin of 21% (standalone 24.6%).
bearish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
FY26 revenue decline of early-to-mid double digits
Management revised FY26 revenue outlook to reflect an early-to-mid double-digit decline due to timing and product mix issues.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1